Maxim Group Downgrades Reed’s to Hold
Maxim Group analyst Anthony Vendetti downgrades Reed's (NASDAQ:REED) from Buy to Hold.
Reed’s Lowers FY22 Revenue Outlook To $56M – $59M From $59M – $62M Prior, Vs. $60.35M Estimate
FY 2022 Financial Guidance and Outlook
Reed's expects 2022 net sales to range between approximately $56-59 million, reflecting growth of approximately 13-19% from 2021. The Company also expects gross margin in 2022
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 517 companies set new 52-week lows.
Reed’s’s Return On Capital Employed Insights
Reed's (NASDAQ:REED) brought in sales totaling $13.72 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 1.95%, resulting in a loss of $5.08 million.
Reed’s Q2 EPS $(0.05) Down From $(0.04) YoY, Sales $13.72M Miss $14.37M Estimate
Reed's (NASDAQ:REED) reported quarterly losses of $(0.05) per share. This is a 25 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $13.72 million
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell
• Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
Gainers
Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.
This Healthcare Stock Jumps Around 188%, Here’s 83 Biggest Movers From Yesterday
Gainers
Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.